BioLargo Cuts AEC PFAS Treatment Energy Use by >90%, Unlocking Commercial-Scale Water Solutions with Unmatched Total Life Cycle Cost Savings

Stock Information for Revance Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revance Therapeutics Inc.

BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough
BioLargo to Present at NobleCon's 21st Annual Emerging Growth Equity Conference, Dec. 2-3, 2025
BioLargo Reports Q3 2025 Operating and Financial Results
BioLargo Q3 2025 Earnings Results Webcast and Conference Call on Friday, November 14th, 2025 - 4:30 PM Eastern Time
BioLargo Subsidiary Clyra Medical Technologies Forms Strategic Alliance with Advanced Solution to Launch ViaCLYR(TM) Wound Irrigation Solution Nationwide
BioLargo Files Federal Lawsuit Against Pooph Inc.
BioLargo Presentation Deck at LD Micro Event Available Online
Biolargo Invites You to the Sustain SoCal 16th Annual Energy Event - A Premier Gathering for Clean Energy Innovation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.